Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation

被引:1
作者
Elsebaey, Mohamed A. [1 ]
Elbedewy, Tamer A. [1 ]
Elashry, Heba [2 ]
Elrefaey, Waleed [1 ]
Elshweikh, Samah A. [1 ]
Elhadidy, Ahmed A. [1 ,9 ]
Shalaby, Neveen A. [1 ]
Elsokkary, Assem Mohamed [3 ]
Elashtokhy, Hossam Eldin A. [4 ]
Abo-Amer, Yousry Esam-Eldin [5 ]
Abo-Elfetoh, Ashraf Rafat [5 ]
Hassanien, Sharaf Elsayed Ali [6 ]
Fouad, Amina [7 ]
Abdellatif, Raghda Samir [7 ]
Ismail, Amro Abdelaziz Mohammed [8 ]
机构
[1] Tanta Univ, Fac Med, Internal Med Dept, Tanta, Egypt
[2] Tanta Univ, Fac Med, Trop Med Dept, Tanta, Egypt
[3] Mansoura New Gen Hosp, Internal Med Dept, Mansoura, Egypt
[4] Tanta Canc Ctr, Med Oncol Dept, Tanta, Egypt
[5] Mahala Hepatol Teaching Hosp, Hepatol Gastroenterol & Infect Dis Dept, Gharbiya, Egypt
[6] Benha Univ, Fac Med, Hepatol Gastroenterol & Infect Dis Dept, Banha, Egypt
[7] Natl Hepatol & Trop Med Res Inst, Clin Pathol Dept, Cairo, Egypt
[8] Cairo Univ, Fac Med, Internal Med Dept, Cairo, Egypt
[9] Tanta Univ, Fac Med, Dept Internal Med, Tanta, Egypt
关键词
antiviral prophylaxis; hepatitis B virus reactivation; immunosuppressive therapy; resolved hepatitis B virus; viral monitoring; VIRUS HBV REACTIVATION; ANTIVIRAL PROPHYLAXIS; LYMPHOMA PATIENTS; CELL LYMPHOMA; CHEMOTHERAPY; PREVENTION; MANAGEMENT; ENTECAVIR; DISEASES; AGENTS;
D O I
10.1097/MD.0000000000031962
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Risk of hepatitis B virus reactivation (HBVr) in patients with resolved HBV infection receiving immunosuppressive therapy has been a growing concern, particularly in the era of biological and targeted therapies. HBV monitoring versus antiviral prophylaxis against HBVr in those patients remains controversial. The aim of the study was to determine the incidence of HBVr and HBV-related hepatitis in resolved HBV patients who received immunosuppressive therapy with or without antiviral prophylaxis. This retrospective study included 64 patients with resolved HBV infection who received different regimens of immunosuppressive medications, with moderate risk of HBVr, for variable underlying diseases. Patients who had chronic HBV infection or other viral infections were excluded. Patients who received B-cell depleting therapies were ruled out. They were divided into 2 groups: group 1 included 31 patients who received immunosuppressive therapy without antiviral prophylaxis, and group 2 included 33 patients who received antiviral prophylaxis (entecavir) within 2 weeks of commencing the immunosuppressive therapy. HBVr, HBV-related hepatitis, and HBV-unrelated hepatitis were assessed along a 1-year duration. The overall HBVr incidence was 1.56% (1/64). This patient who had HBVr was seen in group 1. There were no significant differences between the 2 groups regarding the incidence of HBVr, HBV-related hepatitis, HBV-unrelated hepatitis, and immunosuppressive therapy interruption along a 1-year duration. Based on this retrospective study, close monitoring was equal to antiviral prophylaxis regarding the outcome of resolved HBV patients who received moderate risk immunosuppressive therapy. HBV treatment should commence once HBVr is confirmed.
引用
收藏
页数:6
相关论文
共 33 条
[1]   Optimal Antiviral Prophylaxis Against Hepatitis B Reactivation in Patients Receiving Rituximab-Based Chemotherapy for Lymphoma [J].
Abramson, Jeremy S. ;
Chung, Raymond T. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 312 (23) :2505-2507
[2]   Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection [J].
Barone, Michele ;
Notarnicola, Antonella ;
Lopalco, Giuseppe ;
Viggiani, Maria Teresa ;
Sebastiani, Francesco ;
Covelli, Michele ;
Iannone, Florenzo ;
Avolio, Alfonso W. ;
Di Leo, Alfredo ;
Cantarini, Luca ;
Lapadula, Giovanni .
HEPATOLOGY, 2015, 62 (01) :40-46
[3]   HBV Reactivation During the Treatment of Non-Hodgkin Lymphoma and Management Strategies [J].
Cao, Xing ;
Wang, Yafei ;
Li, Panyun ;
Huang, Wei ;
Lu, Xiaojuan ;
Lu, Hongda .
FRONTIERS IN ONCOLOGY, 2021, 11
[4]   Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review [J].
Cholongitas, Evangelos ;
Haidich, Anna-Bettina ;
Apostolidou-Kiouti, Fani ;
Chalevas, Parthenis ;
Papatheodoridis, George V. .
ANNALS OF GASTROENTEROLOGY, 2018, 31 (04) :480-490
[5]   Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan [J].
Fukuda, Wataru ;
Hanyu, Tadamasa ;
Katayama, Masaki ;
Mizuki, Shinichi ;
Okada, Akitomo ;
Miyata, Masayuki ;
Handa, Yuichi ;
Hayashi, Masatoshi ;
Koyama, Yoshinobu ;
Arii, Kaoru ;
Kitaori, Toshiyuki ;
Hagiyama, Hiroyuki ;
Urushidani, Yoshinori ;
Yamasaki, Takahito ;
Ikeno, Yoshihiko ;
Suzuki, Tsuyoshi ;
Omoto, Atsushi ;
Sugitani, Toshifumi ;
Morita, Satoshi ;
Inokuma, Shigeko .
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (06) :1051-1056
[6]   Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies: two case reports [J].
Grossi, Glenda ;
Vigano, Mauro ;
Facchetti, Floriana ;
Labanca, Sara ;
Loglio, Alessandro ;
Dodero, Anna ;
Montefusco, Vittorio ;
Corradini, Paolo ;
Cafro, Anna ;
Cairoli, Roberto ;
Colombo, Massimo ;
Lampertico, Pietro .
HAEMATOLOGICA, 2017, 102 (10) :E423-E426
[7]   Randomized Controlled Trial of Entecavir Prophylaxis for Rituximab-Associated Hepatitis B Virus Reactivation in Patients With Lymphoma and Resolved Hepatitis B [J].
Huang, Yi-Hsiang ;
Hsiao, Liang-Tsai ;
Hong, Ying-Chung ;
Chiou, Tzeon-Jye ;
Yu, Yuan-Bin ;
Gau, Jyh-Pyng ;
Liu, Chun-Yu ;
Yang, Muh-Hwa ;
Tzeng, Cheng-Hwai ;
Lee, Pui-Ching ;
Lin, Han-Chieh ;
Lee, Shou-Dong .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (22) :2765-+
[8]   Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group [J].
Kim, Seok Jin ;
Hsu, Chiun ;
Song, Yu-Qin ;
Tay, Kevin ;
Hong, Xiao-Nan ;
Cao, Junning ;
Kim, Jin Seok ;
Eom, Hyeon Seok ;
Lee, Joon Hyeok ;
Zhu, Jun ;
Chang, Kian-Meng ;
Reksodiputro, Arry Harryanto ;
Tan, Daryl ;
Goh, Yeow Tee ;
Lee, Jejung ;
Intragumtornchai, Tanin ;
Chng, Wee-Joo ;
Cheng, Ann-Lii ;
Lim, Soon Thye ;
Suh, Cheolwon ;
Kwong, Yok-Lam ;
Kim, Won Seog .
EUROPEAN JOURNAL OF CANCER, 2013, 49 (16) :3486-3496
[9]   Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians [J].
Koffas, Apostolos ;
Dolman, Grace E. ;
Kennedy, Patrick T. F. .
CLINICAL MEDICINE, 2018, 18 (03) :212-218
[10]   Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations [J].
Koutsianas, Christos ;
Thomas, Konstantinos ;
Vassilopoulos, Dimitrios .
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2020, 12